Video
Dr. Tripathy Discusses Neratinib in HER2+ Breast Cancer
Author(s):
Debu Tripathy, MD, professor of medicine, chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses neratinib (Nerlynx) for the treatment of patients with HER2-positive breast cancer.
Debu Tripathy, MD, professor of medicine, chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses neratinib (Nerlynx) for the treatment of patients with HER2-positive breast cancer.
Neratinib was approved by the FDA in July 2017 for the extended adjuvant treatment of patients with early stage, HER2-positive breast cancer following postoperative trastuzumab (Herceptin).
Tripathy says that this drug initially showed a small advantage in this population, but with longer follow-up the improvement is growing, with a 5% difference in recurrence rate.
